基于肝硬化分期与HVPG的静脉曲张出血后风险分层策略
本研究纳入193例肝硬化静脉曲张出血后7天内患者,在普萘洛尔/纳多洛尔联合内镜套扎治疗前及治疗1-3个月时测量HVPG,随访4年。结果显示,仅对合并腹水/肝性脑病且基线HVPG>16 mmHg的患者测量HVPG应答,可减少42%的HVPG测量次数,并将「灰色地带」从46%降至35%,验证队列(n=231)证实该结果。
要点
- HVPG应答者再出血风险10% vs 34%,生存率61% vs 39%。
- 合并腹水/肝性脑病且基线HVPG≤16 mmHg者再出血风险低(13%)。
- 仅对腹水/肝性脑病且基线HVPG>16 mmHg者测HVPG应答可减少42%测量。
核心结论
- 将HVPG测量限制于合并腹水/肝性脑病患者,且仅当基线HVPG>16 mmHg时才测量HVPG应答,可提高高危患者检出并显著减少HVPG测量次数。
研究设计与样本
- 前瞻性队列研究,纳入193例肝硬化静脉曲张出血后7天内患者,62%合并腹水/肝性脑病,在普萘洛尔/纳多洛尔联合内镜套扎治疗前及治疗1-3个月时测量HVPG,随访4年。
- 验证队列231例。
主要发现
- 随访期间45例发生静脉曲张出血,61例死亡。
- HVPG应答者(n=71)再出血风险低于非应答者(n=122)(10% vs 34%,P=0.001),生存率更高(61% vs 39%,P=0.001)。
- 合并肝性脑病者(n=120)生存率低于无肝性脑病者(40% vs 63%,P=0.005)。
- 合并腹水/肝性脑病且基线HVPG≤16 mmHg者(n=16)再出血风险低(13%)。
- 合并腹水/肝性脑病且基线HVPG>16 mmHg者中,仅HVPG应答者(n=32)预后良好,再出血风险7% vs 39%(P=0.018),生存率56% vs 30%(P=0.010)。
关键数值与推荐
- HVPG应答定义为HVPG较基线下降≥20%或≤12 mmHg。
- 推荐策略:仅对合并腹水/肝性脑病且基线HVPG>16 mmHg的患者测量HVPG应答。
- 该策略将「灰色地带」(高危但随访未死亡患者)从46%降至35%,减少42%的HVPG测量次数。
临床怎么用
- 临床可依据肝硬化分期(是否合并腹水/肝性脑病)和基线HVPG水平简化静脉曲张出血后的风险分层。
- 对合并腹水/肝性脑病且基线HVPG>16 mmHg的患者,应评估HVPG应答以识别高危非应答者。
- 对基线HVPG≤16 mmHg的腹水/肝性脑病患者,再出血风险较低,可减少HVPG测量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: A hepatic venous pressure gradient (HVPG) decrease of 20% or more (or ≤12 mm Hg) indicates a good prognosis during propranolol/nadolol treatment but requires two HVPG measurements. We aimed to simplify the risk stratification after variceal bleeding using clinical data and HVPG. METHODS: A total of 193 patients with cirrhosis (62% with ascites and/or hepatic encephalopathy [HE]) who were within 7 days of bleeding had their HVPG measured before and at 1-3 months of treatment with propranolol/nadolol plus endoscopic band ligation. The endpoints were rebleeding and rebleeding/transplantation-free survival for 4 years. Another cohort (n = 231) served as the validation set. RESULTS: During follow-up, 45 patients had variceal bleeding and 61 died. The HVPG responders (n = 71) had lower rebleeding risk (10% vs. 34%, P = 0.001) and better survival than the 122 nonresponders (61% vs. 39%, P = 0.001). Patients with HE (n = 120) had lower survival than patients without HE (40% vs. 63%, P = 0.005). Among the patients with ascites/HE, those with baseline HVPG ≤ 16 mm Hg (n = 16) had a low rebleeding risk (13%). In contrast, among patients with ascites/HE and baseline HVPG > 16 mm Hg, only the HVPG responders (n = 32) had a good prognosis, with lower rebleeding risk and better survival than the nonresponders (n = 72) (respective proportions: 7% vs. 39%, P = 0.018; 56% vs. 30% P = 0.010). These findings allowed us to develop a strategy for risk stratification in which HVPG response was measured only in patients with ascites and/or HE and baseline HVPG > 16 mm Hg. This method reduced the "gray zone" (i.e., high-risk patients who had not died on follow-up) from 46% to 35% and decreased the HVPG measurements required by 42%. The validation cohort confirmed these results. CONCLUSIONS: Restricting HVPG measurements to patients with ascites/HE and measuring HVPG response only if the patient's baseline HVPG is over 16 mm Hg improves detection of high-risk patients while markedly reducing the number of HVPG measurements required.
引用
- La Mura V, Garcia-Guix M, Berzigotti A, et al. A Prognostic Strategy Based on Stage of Cirrhosis and HVPG to Improve Risk Stratification After Variceal Bleeding. Hepatology. 2020. PMID: 31960441. doi:10.1002/hep.31125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。